# Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

Study · id `cardio:ct-nct02744339` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02744339](<https://clinicaltrials.gov/study/NCT02744339>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02744339

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 118 participants.

## Technical summary

Registry record NCT02744339. Randomized; double masking; primary purpose treatment. Start 2016-03 (actual); primary completion 2020-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 118 participants (enrolled count; ClinicalTrials.gov record NCT02744339, source copy `cardio:ctgov-nct02744339-2020-11-04`, retrieved 2026-10-31)
- Started: 2016-03 (actual) (ClinicalTrials.gov record NCT02744339, source copy `cardio:ctgov-nct02744339-2020-11-04`, retrieved 2026-10-31)
- Primary completion: 2020-08 (actual) (ClinicalTrials.gov record NCT02744339, source copy `cardio:ctgov-nct02744339-2020-11-04`, retrieved 2026-10-31)
- Completion: 2020-09 (actual) (ClinicalTrials.gov record NCT02744339, source copy `cardio:ctgov-nct02744339-2020-11-04`, retrieved 2026-10-31)
- Countries: Austria (ClinicalTrials.gov record NCT02744339, source copy `cardio:ctgov-nct02744339-2020-11-04`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02744339-2020-11-04`, retrieved 2026-10-31)

## The registry's words

- Brief title: Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
- Acronym: DYNAMIC
- Condition: Hypertension, Pulmonary
- Condition: Heart Failure With Normal Ejection Fraction
- Intervention (Drug): Riociguat
- Intervention (Drug): Placebo
- Lead sponsor: Medical University of Vienna
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Medical University of Vienna (`cardio:org-medical-university-of-vienna`)

## Provenance

Content hash: 332b8ac6f3ac18cca7fcd144253755d8e53797bcf1d6f34b705057aec66f26b9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
